Ocular Therapeutix Inc (OCUL) Q4 2018 Earnings Conference Call Transcript
OCUL earnings call for the period ending December 31, 2018.
Ocular Therapeutix
OCUL
OCUL
$3.37
-$0.09
0.0%
BATS BZX Real Time Price as of May 20, 2019, 4:30 p.m.
View Interactive OCUL Charts
Ocular Therapeutix, Inc.
News & Analysis: Ocular Therapeutix
All
Market Moves
Earnings
Here's Why Ocular Therapeutix Jumped 21.6% in August
The company reported second-quarter 2018 financial results and an important business update.
Why Ocular Theraputix Inc. Saw Its Stock Price Plummet Today
The FDA rejected its eye-pain treatment for the second time.
Here's Why Ocular Therapeutix Inc Rose 25.6% Today
The biopharma thinks it just fixed its problems with the FDA.
Why Ocular Therapeutix Inc. Got Beat Down Today
A negative article by STAT has investors worried about the approvability of the biotech's eye drug.
Why Ocular Therapeutix Inc Stock Jumped Higher Today
Presentation of positive phase 3 data sent shares higher.
Why Ocular Theraputix Inc. Got Hammered Today
The FDA wants some changes at the biotech's manufacturing plant.
Why Ocular Therapeutix Inc Saw its Share Price Jump Today
Positive patient experience for the company's eye insert, Dextenza, sends shares higher.
Why Ocular Therapeutix Inc Jumped Higher Today
An analyst upgrade ahead of an FDA decision for its eye-pain medication sends shares higher.
Why Shares of Ocular Therapeutix, Inc. Crumbled Today
Shares of Ocular Therapeutix cratered today. Here's why.
